Eight rare urinary disorders in a patient with Kallmann syndrome

A case report

Huining Tian, PhD, Zi Yan, PhD, You Lv, PhD, Lin Sun, PhD, Xiaokun Gang, PhD, Guixia Wang, PhD, MD

Abstract

Rationale: Kallmann syndrome (KS) is a rare inherited genetic disorder characterized by hypogonadotropic hypogonadism and hyposmia/anosmia. Early diagnosis is the key to timely treatment and improvement of prognosis in patients with KS. As the most common complication of KS, renal agenesis can provide clues to early diagnosis and treatment for KS. In this article, we report a case of KS with 8 rare urinary disorders for the first time.

Patient concerns: A 19-year-old Chinese man presented with 8 rare urinary disorders and a history of bilateral cryptorchidism came to us for microgenitum, hyposmia, and delayed puberty.

Diagnosis: The patient presented with hyposmia, low levels of sex hormones and showed a weak response to the GnRH stimulation test leading to a diagnosis of KS. Two missense mutations were found in further whole-exome sequencing: 1) Kallmann syndrome 1 (KAL1) gene in exon11, c.1600G > A, p. Val534Ile; 2) Prokineticin receptor 2 (PROKR2) gene in exon 2, c.533G > A, p. Trp178Ser. which led to a diagnosis of KS.

Interventions: The patient underwent replacement therapy of human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG). The patient had previously undergone six surgeries for cryptorchidism and urinary disorders.

Outcomes: The patient’s puberty retardation was effectively alleviated. His serum testosterone (T) reached a normal level (8.280 nmol/mL). During the follow-up period, he presented with Tanner stage II pubic hair development.

Conclusion: In this article, we report 8 rare urinary disorders with missense mutations of KAL1 and PROKR2 in a case of KS. Among them, bilateral giant kidneys, urinary extravasation of right renal, bilateral mega-ureters, left ureteral terminal obstruction, bilateral renal cyst and bladder emptying disorder are reported for the first time, which enrich the integrity of urinary disorder types and provide clues to genetic counseling in patients with KS.

Abbreviations: BMI = body mass index, FSH = follicle-stimulating hormone, GnRH = Gonadotropin-releasing hormone, HCG = human chorionic gonadotropin, HMG = human menopausal gonadotropin, HRT = hormone replacement therapy, KAL1 = Kallmann syndrome 1, KS = Kallmann syndrome, LH = luteinizing hormone, P = progesterone, PROKR2 = Prokineticin receptor 2, T = testosterone.

Keywords: Kallmann syndrome, renal agenesis/dysgenesis, urinary disorders, KAL1

1. Introduction

Kallmann syndrome (KS) is a rare inherited genetic disorder characterized by hypogonadotropic hypogonadism and hyposmia/anosmia. Studies have suggested that KS is associated with more than 20 genes and the mutations in these genes account for approximately 30% of all KS cases. These genes appear to involve in the migration of a group of neurons specialized in the sense of smell as well as neurons producing gonadotropin-releasing hormone (GnRH). KS may present as either a sporadic or a familial case, which contains 3 modes of inheritance: autosomal dominant,
autosomal recessive, and X-linked recessive inheritance. The relationship between clinical phenotypes and gene mutations may provide clues for early diagnosis and therapy. Renal agenesis is considered a signature phenotype of KAL1 mutations and can be used as an early marker for genetic screening. In this article, we for the first time reported a diagnosis of KS in a 19-year-old young man with 8 rare urinary disorders demonstrating a conservative change in the KAL1 gene (c.1600G>A, p. Val534Ile) and the PROKR2 gene (c.533G>A, p. Trp178Ser) in this article.

2. Case presentation

The patient is a 19-year-old Chinese male who presented to our hospital in 2015 for delayed puberty and experienced hyposmia for 3 years. The patient declared that he had experienced hyposmia for 3 years, but he ignored the symptom due to a history of nasitis. There is no relevant history in his family. In 2005, he accepted bilateral testicular traction and fixation for bilateral cryptorchidism, and received HCG (doses unknown) injection after the operation. Then, he was diagnosed with a complex of urinary dysfunctions, including bilateral giant kidneys and hydronephrosis, traumatic rupture of right renal, urinary extravasation of right renal, bilateral megaloo-ureters, left ureteral terminal obstruction, bilateral renal cyst, and bladder emptying disorder. The patient underwent 5 operations for some of the above urinary disorders (Table 1). Pyelography results prior to a surgical operation were shown in Figure 1. He was 167 cm tall and 62 kg in weight (body mass index [BMI] = 22.3 kg/m²). At the age of 15, no pubertal development (no pubic hair) was noted. His penis was 2 cm in length and testicles were both 1.5 ml in volume. He had decreased levels of serum follicle-stimulating hormone (FSH 0.855 mIU/ml, normal range 1.27-19.26 mIU/ml), luteinizing hormone (LH 0.385 mIU/ml, normal range 1.24-8.62 mIU/ml), and T (0.720 nmol/ml, normal range 6.07-27.1 nmol/ml). His progesterone (P) level was elevated (3.440 nmol/l, normal range 0.318-2.671 nmol/l). The diagnosis of hyposmia was confirmed by the olfactory test, showing the ability to distinguish alcohol, water, and vinegar, but not weak amytic substances such as coffee and bread. The results of pituitary MRI showed that there was no abnormal signal, and the pituitary gland was slightly flattened. The patient was suspected of having KS, and therefore a GnRH stimulation test (100 μg GnRH, 2 ml physiological saline, intravenous injection) was performed. FSH and LH levels at 0, 30, 60, and 90 minutes after GnRH injection were tested and the levels of FSH were 0.860, 2.250, 2.950, 3.040 mIU/ml and the levels of LH were 0.400, 0.990, 1.020, 0.860 mIU/ml, respectively. The patient underwent whole-exome sequencing, which identified two genetic defects:

1) a missense mutation in the KAL1 gene: a G to A transition at position 1600 in exon 11, changing codon 534 encoding valine into isoleucine;
2) a missense mutation of PROKR2 gene, a G to A transition at position 533 in exon 2, changing codon 178 encoding tryptophane into serine (Fig. 2).

Combined with the results of clinical manifestation, hormone test, GnRH stimulation test and whole-exome sequencing, the patient was diagnosed as KS. Idiopathic hypogonadotropic hypogonadism (IHH) and CHARGE syndrome, on the other hand, were also considered and precluded.

Table 1

| Date    | Diagnosis                                | Interventions                                                                 |
|---------|------------------------------------------|-------------------------------------------------------------------------------|
| 2005    | bilateral cryptorchidism                 | bilateral testicular traction and fixation, HCG (doses unknown) injection after the operation |
| 2010.05 | traumatic rupture and urinary extravasation of right renal, left renal cyst | gastrostomy of right renal pelvis                                                |
| 2010.06 | fistulostomy prolapse                    | gastrostomy of right renal pelvis                                                |
| 2010.07 | right giant kidneys and hydronephrosis, right giant ureter | loosening of right ureter, replantation of right ureter and bladder               |
| 2013.04 | left varicosities                         | high ligation of left spermatic vein, replantation of left ureter and bladder   |
| 2014.01 | left ureteral terminal obstruction, bilateral hydronephrosis, left giant ureter |                                                                                   |

HCG = human chorionic gonadotropin.

Figure 1. Pyelography results. A. Shot at 15 minutes after pyelography: right pyelectasia, right caliectasis, right uneven megaloo-ureter. B. Shot at 15 minutes after pyelography: left pyelectasia, left caliectasis, left uneven megaloo-ureter.
After 2 years of HCG and human menopausal gonadotropin (HMG) replacement therapy, his serum T reached normal level and Tanner stage II pubic hair development was observed. The details of hormone replacement therapy (HRT) and outcomes were showed in Table 2. However, the patient had no sperm detected in semen analysis.

3. Discussion

According to the literature, the incidence of KS ranges from 1/10,000 in males and 1/50,000 in females, which is 5 times higher in males than in females.[4–6] The main causes of KS are the impairment of olfactory axis development and of GnRH neurons migration caused by gene mutations.[6] The primary purpose of treatment for male patients is to promote masculine development, and the second is to restore the gonadal function and even fertility of patients who are eager to give birth.[7]

As one of the few treatable infertility, early diagnosis and treatment of KS are particularly important. Renal agenesis is the most common complication for KS patients, which may provide clues for the early diagnosis and treatment of the patient. Fourteen types of urinary disorders in the KS patients have been reported before, including renal agenesis (unilateral and bilateral),[4] renal malrotation,[6] bilateral dilatation of the calyces and pelves,[8]

| Date    | Height (cm) | Weight (kg) | Testicular volume (ml) | Penis (cm) | T (normal range: 0.07–27.1nmol/ml) | FSH (normal range: 1.27–19.26mIU/mL) | LH (normal range: 1.24–8.62LmIU/ml) | Interventions                  |
|---------|-------------|-------------|------------------------|------------|----------------------------------|-----------------------------------|----------------------------------|--------------------------------|
| 2015.07 | 167         | 62          | 1.5                    | 2          | 0.720                            | 0.885                             | 0.385                            | HCG 2000U biw                   |
| 2016.02 | 167         | 64          | 1.5                    | N/A        | 0.610                            | 0.730                             | 0.240                            | HCG 2000U biw                   |
| 2016.04 | 167         | 64          | 1.6–2.0                | N/A        | 3.820                            | 1.310                             | 0.300                            | HCG 2000U qiw, HMG 75U qiw     |
| 2016.07 | 169         | 65.3        | 2.0–3.0                | 4          | 1.220                            | N/A                               | N/A                              | HCG 2000U qiw, HMG 75U qiw     |
| 2016.11 | 170         | 66          | N/A                    | N/A        | 0.330                            | 2.290                             | 0.430                            | HCG 2000U fiv, HMG 75U qiw     |
| 2017.03 | 172         | 77.5        | 2.0–3.0                | 5          | 5.540                            | 3.780                             | 0.350                            | HCG 2000U fiv, HMG 75U qiw     |
| 2017.06 | 175         | 76          | N/A                    | N/A        | 13.010                           | N/A                               | N/A                              | HCG 2000U qiw, HMG 75U qiw     |
| 2017.10 | 175         | 76          | 3.0–4.0                | 5.5        | 8.280                            | 2.760                             | 0.130                            | HCG 2000U qiw, HMG 75U qiw     |

Note: biw=twice a week, HCG=Human Chorionic Gonadotropin, HMG=Human Menopausal Gonadotropin, tid=three times a week, TUC=Testosterone Undecanoate Capsules, TUI=Testosterone Undecanoate Injection, qiw=3 times a week, qiv=once a week.
horseshoe kidneys,[9] multicystic dysplastic kidneys,[10] vesicoureteral reflux,[10,11] ectopic right ureteric orifice,[12] left hydrenephrosis,[11] left reflux,[11] and hydroureter.[11] In this case, we reported 8 rare urinary disorders co-exist in one patient, in which bilateral giant kidneys, urinary extravasation of right renal, bilateral megalou-ureters, left ureteral terminal obstruction, bilateral renal cyst and bladder emptying disorder have not been reported before.

*KAL1* is a well-known gene most closely related to KS-associated renal agenesis. Moreover, renal agenesis was only found in male patients and occurred in 31.8% KS patients due to *KAL1* defects, consistent with the percentage of renal agenesis (31%) in X-linked KS patients in the study by Quinton et al.[13] Therefore, we could imply that renal agenesis may be a marker of *KAL1* mutation in KS patients with an estimated sensitivity of 30%. In the present study, our patient was first detected with two-point mutations in the *KAL1* gene. However, one is a G-to-A transition at position 1600 in exon 11, changing codon 534 from valine to isoleucine with a carrier rate of 59.16%, suggesting that mutation at this position has no genotype-phenotype correlation. The other mutation is a synonymous mutation of a C-to-T transition in exon 12. Next, we performed a whole-exome sequencing for the patient and identified a G-to-A transition in exon 2 in the *PROKR2* gene, changing codon 178 from tryptophan to serine with a carrier frequency of 0.01813%. *PROKR2* is located on the autosomal chromosome region 20p13 and is mainly expressed in the brain, olfactory bulbs, and testes.[14] To the best of our knowledge, KS patients with a *PROKR2* mutation presenting urinary disorders have not been reported elsewhere, and the associated genetic links were unclear. We suspected that a single mutation of KS-related genes may not have significant clinical performance, but multiamutations may have an accumulation effect.[21] Therefore, when co-mutation with other KS-related genes such as *PROKR2, KAL1* with p.V334I mutation may lead to a novel presentation of urinary disorders. We also searched for KS patients with urinary disorders in the absence of *KAL1* mutation. Remarkably, another *KAL1* mutation at position c.1600G > A (p.V534I) in exon11 in a patient with bilateral abnormal rotation and bimanual synkinesias was found.[15] Whether this interaction intersects with other KS-related genes to cause certain clinical phenotypes in KS, or other genes associated with KS-related urinary disorders need to be explored is yet unclear. More cases are required for genome, transcriptome, proteomics, and metabolomics analysis.

In this report, the patient accepted bilateral testicular traction and fixation, and received HCG injection after the operation. As shown in Table 2, after two years of HCG and HMG treatment, the patient’s T level reached normal level and developed male secondary sexual characteristics. However, the LH level of the patient was still lower than normal, and no sperm was detected in semen analysis. The results of the GnRH stimulation test also showed that the LH value was much lower than the normal value after GnRH stimulation. FSH and LH values were about 3 times higher than those before injection, indicating that the patient had normal GnRH response. GnRH treatment provides pulse management of GnRH via a mini-infusion pump, which should be used to induce spermatogenesis and fertility for our patient in the future.[16]

4. Conclusions

In conclusion, we report 8 novel urinary disorders with missense mutations of *KAL1* and *PROKR2* in a case of KS for the first time, which enrich the integrity of urinary disorder types in patients with KS. Urinary disorders and cryptorchidism can be a hint for the occurrence of hypogonadotropic hypogonadism requiring the attention of doctors for early diagnosis and treatment. More studies on the genotype-phenotype correlation need to be done, especially between *KAL1* mutation and KS related urinary disorders. Identification of this correlation may be helpful for an early and precise diagnosis, and lays the foundation of timely and effective treatment.

5. Ethical approval

Institutional review board/ethics committee approval was obtained from the Institutional Review Board of the First Hospital of Jilin University.

Acknowledgments

We want to acknowledge the patient and his family for their support and cooperation.

Author contributions

Conceptualization: Huining Tian, Xiaokun Gang, Guixia Wang

Data curation: Huining Tian

Formal analysis: Huining Tian

Funding acquisition: Guixia Wang

Investigation: You Lv, Lin Sun

Methodology: Zi Yan

Project administration: Guixia Wang, Xiaokun Gang

Resources: Guixia Wang

Validation: Guixia Wang, Xiaokun Gang

Visualization: Guixia Wang, Xiaokun Gang

Writing – original draft: Huining Tian

Writing – review & editing: Zi Yan.

References

[1] Sonne J, Lopez-Ojeda W. Kallmann Syndrome. Treasure Island (FL): In: StatPearls; 2019.
[2] Kim SH. Congenital hypogonadotropic hypogonadism and kallmann syndrome: past, present, and future. Endocrinol Metab (Seoul) 2015;30: 456–66.
[3] Stamou MI, Plummer L, Galli-Tsinopoulou A, et al. Unilateral renal agenesis as an early marker for genetic screening in Kallmann syndrome. Hormones (Athens) 2019;18:103–5.
[4] Laitinen EM, Vaaralahti K, Tammisa K, et al. Incidence, phenotypic features and molecular genetics of Kallmann syndrome in Finland. Orphanet J Rare Dis 2011;6:41.
[5] Meczkański B, Podlguńska-Stopa A, Smolarczyk R, et al. Kallmann syndrome in women: from genes to diagnosis and treatment. Gynecol Endocrinol 2013;29:296–300.
[6] Cariboni A, Maggi R. Kallmann’s syndrome, a neuronal migration defect. Cell Mol Life Sci 2006;63:2512–26.
[7] Young J, Xu C, Papadakis GE, et al. Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocr Rev 2019;40:669–710.
[8] Zenteno JC, Mendez JP, Maya-Nunez G, et al. Renal abnormalities in patients with Kallmann syndrome. BJU Int 1999;83:383–5.
[9] Trarbach EB, Monilho IL, Portuncula CGG, et al. Similar interstitial deletions of the KAL-1gene in two Brazilian families with X-linked Kallmann Syndrome. Genet Mol Biol 2004;27:337–41.
[10] Sat0 N, Katsumata N, Kagami M, et al. Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab 2004;89:1079–86.
[11] Martel P, Pineda J, Levilliers J, et al. Hypogonadotropic hypogonadism with hyposmia, X-linked ichthyosis, and renal malformation syndrome. Clin Endocrinol (Oxf) 1995;42:121–8.

[12] Izumi Y, Tsutsui K, Okamoto S, et al. A novel mutation of the KAL1 gene in Kallmann syndrome. Endocr J 1999;46:651–8.
[13] Quinton R, Duke VM, Robertson A, et al. Idiopathic gonadotrophin deficiency: genetic questions addressed through phenotypic characterisation. Clin Endocrinol (Oxf) 2001;55:163–74.

[14] Sarfati J, Dode C, Young J. Kallmann syndrome caused by mutations in the PROK2 and PROKR2 genes: pathophysiology and genotype-phenotype correlations. Front Horm Res 2010;39:121–32.

[15] Maya-Nunez G, Zenteno JC, Ulloa-Aguirre A, et al. A recurrent missense mutation in the KAL gene in patients with X-linked Kallmann’s syndrome. J Clin Endocrinol Metab 1998;83:1650–3.

[16] Hoffman AR, Crowley WFJr. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med 1982;307:1237–41.